4:07 PM
 | 
Oct 18, 2017
 |  BC Extra  |  Company News

Priority Review for Lynparza to treat breast cancer

FDA granted Priority Review to an sNDA for Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) to treat patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously been treated with...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >